Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study.
Active treatment
COVID-19
Cancer
Chemotherapy
Incidence
Outpatients
Journal
Seminars in oncology
ISSN: 1532-8708
Titre abrégé: Semin Oncol
Pays: United States
ID NLM: 0420432
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
23
11
2020
revised:
20
01
2021
accepted:
20
01
2021
pubmed:
10
4
2021
medline:
9
11
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
Leading scientific societies have recommended delaying and/or suspending active cancer treatment during the COVID-19 pandemic. Nevertheless, data on this novel infection in patients with a diagnosis of cancer receiving active treatment are scarce and it is unknown if these recommendations could have repercussions on future progress of the disease. The main objective of this study is to learn the COVID-19 incidence rate in outpatients with cancer receiving active treatment. This work is a retrospective cohort study that included all patients with a diagnosis of cancer who received active cancer treatment in two Andalusian hospitals between February 26 and May 13, 2020. Variables regarding the patient, tumor, and development of COVID-19 were collected. A descriptive analysis was performed and the cumulative incidence of COVID-19 in these patients was evaluated. A total of 673 patients were included. The median age was 62 years. There was a low rate of comorbidity and 12.1% had an ECOG >2. Breast cancer was the most common cancer (41%), followed by colorectal and lung cancer. Stage IV cancer was reported in 52.7% of patients. The most common treatment was chemotherapy (53.9%). Treatment was delayed or suspended in 6% of patients. Only three patients developed COVID-19. The cumulative incidence was 0.44% and one person died due to infection. In the present retrospective cohort study we found a low incidence of COVID-19 infection in patients with cancer receiving active treatment in an outpatient setting. The sociodemographic factors of Andalusia may explain why these results differ from those presented by other colleagues in Spain, but raise questions about whether universal recommendations may put the benefits of antineoplastic therapy at risk.
Sections du résumé
BACKGROUND
Leading scientific societies have recommended delaying and/or suspending active cancer treatment during the COVID-19 pandemic. Nevertheless, data on this novel infection in patients with a diagnosis of cancer receiving active treatment are scarce and it is unknown if these recommendations could have repercussions on future progress of the disease. The main objective of this study is to learn the COVID-19 incidence rate in outpatients with cancer receiving active treatment.
METHODS
This work is a retrospective cohort study that included all patients with a diagnosis of cancer who received active cancer treatment in two Andalusian hospitals between February 26 and May 13, 2020. Variables regarding the patient, tumor, and development of COVID-19 were collected. A descriptive analysis was performed and the cumulative incidence of COVID-19 in these patients was evaluated.
RESULTS
A total of 673 patients were included. The median age was 62 years. There was a low rate of comorbidity and 12.1% had an ECOG >2. Breast cancer was the most common cancer (41%), followed by colorectal and lung cancer. Stage IV cancer was reported in 52.7% of patients. The most common treatment was chemotherapy (53.9%). Treatment was delayed or suspended in 6% of patients. Only three patients developed COVID-19. The cumulative incidence was 0.44% and one person died due to infection.
CONCLUSIONS
In the present retrospective cohort study we found a low incidence of COVID-19 infection in patients with cancer receiving active treatment in an outpatient setting. The sociodemographic factors of Andalusia may explain why these results differ from those presented by other colleagues in Spain, but raise questions about whether universal recommendations may put the benefits of antineoplastic therapy at risk.
Identifiants
pubmed: 33832767
pii: S0093-7754(21)00002-6
doi: 10.1053/j.seminoncol.2021.01.002
pmc: PMC7846234
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-151Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Transl Oncol. 2020 Dec;22(12):2364-2368
pubmed: 32449128
Eur J Cancer. 2020 Aug;135:242-250
pubmed: 32586724
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319